title: High-dose-intensity combination chemotherapy for advanced sarcomas: a pilot study.
abstract: A new polychemotherapy schedule involving high dose intensity and shortened intervals has been developed for patients with advanced sarcomas. Mesna at 2500 mg/m2 for 3 days, epidoxorubicin at 60 mg/m2 on day 1, ifosfamide at 2500 mg/m2 for 3 days, and dacarbazine at 450 mg/m2 for 2 days were given every 2 weeks to a consecutive series of 20 patients. All patients received granulocyte colony-stimulating factor (G-CSF; Filgrastim) subcutaneously at 300 microg from day 5 to day 12 of each cycle. The treatment was feasible and toxicity was acceptable, with grade IV myelotoxicity being observed only in one case. In all, 6 of 14 evaluable patients had an objective response; the median survival was 12 months. Toxicity was milder than that observed for the classic combination MAID, and the planned dose intensity was maintained in the majority of cases.
authors.affiliation: Oncologia Medica-Ospedale S. Andrea, Località Felettino, La Spezia, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Pronzato
authors.forename: P
authors.initials: P
authors.lastname: Losardo
authors.forename: F
authors.initials: F
authors.lastname: Pensa
authors.forename: A
authors.initials: A
authors.lastname: Tognoni
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D006403:Hematologic Tests; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D007262:Infusions, Intravenous; D008297:Male; D015080:Mesna / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy; D010865:Pilot Projects; D011994:Recombinant Proteins; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D003606:Dacarbazine; D004317:Doxorubicin; D015080:Mesna; D000069585:Filgrastim; D007069:Ifosfamide